• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting

    9/8/25 9:00:00 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BMRN alert in real time by email

    Children who received VOXZOGO showed anatomical improvements in spinal morphology

    VOXZOGO continued to significantly improve growth in children who received the medicine after puberty onset

    SAN RAFAEL, Calif., Sept. 8, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced new data from 14 studies were presented at the American Society for Bone and Mineral Research 2025 (ASBMR) Annual Meeting in Seattle, including results demonstrating treatment with VOXZOGO® (vosoritide) led to anatomical improvements in spinal morphology in young children, and continued efficacy in children who received the medicine after the onset of puberty.

    BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

    VOXZOGO Demonstrated Positive Impact on Spinal Morphology

    An analysis of data from the randomized, double-blind, placebo-controlled Phase 2 CANOPY clinical study (111-206) in children ages 5 and under with achondroplasia examined the impact of VOXZOGO on spinal morphology, one of the factors that can lead to spinal stenosis, a serious complication of the condition where clinical evidence is limited. Spinal stenosis often results in narrowing of the spinal canal and additional pressure on the spinal cord and nerve roots, resulting in a host of symptoms in children, including pain, numbness, difficulty walking and bladder issues.

    Researchers found that children (n=40) who received VOXZOGO for 52 weeks experienced measurable improvement in interpedicular distance (IPD) and greater spinal canal width in all five vertebrae in the lower back (L1 through L5) compared to children who received placebo (n=27). Children who received VOXZOGO (57%) in this study also demonstrated a reduction in thoracolumbar kyphosis (TLK), or excessive curvature of the spine, compared to those who received placebo (33%).

    "The impact of achondroplasia on the spine can lead to great discomfort and, in some cases, disability in children living with the condition, with symptoms persisting well into adulthood," said Greg Friberg, M.D., Executive Vice President and Chief Research & Development Officer at BioMarin. "VOXZOGO is the only approved medicine with data supporting a positive impact on spinal morphology, which could potentially lead to clinical improvements in painful characteristics associated with achondroplasia, such as spinal stenosis. Today's research adds to the immense body of evidence demonstrating how VOXZOGO's benefit can extend beyond improving growth and may reduce the significant complications associated with achondroplasia in children."

    Results from the open-label, Phase 3 CANOPY long-term extension study (111-302) examined whether teenagers with achondroplasia continued to benefit from the medicine after puberty onset compared to untreated children. In young men (mean age of puberty onset = 12.1 years) who received VOXZOGO (n=33), researchers found that the participants experienced 24.62 cm of growth from the mean age of puberty onset until age 18 compared to 17.07 cm in untreated individuals, a difference of 7.55 cm. For young women (mean age of puberty onset = 10.7 years), growth from the mean age of puberty until age 16 was 21.20 cm compared to 13.13 cm in untreated individuals, a difference of 8.07 cm. VOXZOGO is approved in children of all ages with achondroplasia until their growth plates close, which typically occurs several years after the onset of puberty.

    Observational Studies Reinforce Unmet Need in ENPP1 Deficiency

    BioMarin presented research from four studies reflecting its leadership in deepening the scientific understanding of and highlighting the unmet medical needs for people with ENPP1 deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones. BioMarin is advancing BMN 401, a potential first-in-disease enzyme therapy for the condition. Initial pivotal data readout for the ENERGY 3 study in children ages 1-12 years with ENPP1 deficiency is anticipated in the first half of 2026, with potential launch in 2027.

    Below are key presentations for BioMarin (all times in Pacific Time):

    VOXZOGO and Skeletal Conditions

    Effect of Long-Term Vosoritide Treatment in Pediatric Participants With Achondroplasia on Bone Mineral Density and Bone Content: Results From Quantitative Computed Tomography Analyses

    Oral Presentation (pre-meeting)

    Thursday, Sept. 4, 9:25 a.m.

    Poster #Sat-572

    Saturday, Sept. 6, 2 – 3:30 p.m.

    Comprehensive Analysis of FGFR3 Variants Identified >10 Candidate Hypochondroplasia Variants with Potential to Increase Diagnostic Yield

    Plenary Poster #Fri-506

    Friday, Sept. 5, 5 – 6:30 p.m.

    Poster #Sun-506

    Sunday, Sept. 7, 2 – 3:30 p.m.

    C-Type Natriuretic Peptide (CNP) Agonist CNP38 Improves Growth in the Hyp Mouse Model of XLH

    Plenary Poster #Fri-266

    Friday, Sept. 5, 5 – 6:30 p.m.

    Poster #Sat-266

    Saturday, Sept. 6, 2 – 3:30 p.m.

    Continued Growth After Puberty in Participants With Achondroplasia Treated With Vosoritide in a Phase 3 Long-Term Extension Trial

    Poster #Sat-555

    Saturday, Sept. 6, 2 – 3:30 p.m.

    CNP Agonism: A Novel Anabolic Approach for Osteoporosis

    Poster #Sat-580

    Saturday, Sept. 6, 2 – 3:30 p.m.

    Vosoritide, a C-Type Natriuretic Peptide (CNP) Analog, Alone and in Combination with Alendronate Improves Incidence of New Fractures and Long Bone Growth in the OIM Mouse Model for Osteogenesis Imperfecta: A Promising Therapeutic Approach

    Poster #Sat-297

    Saturday, Sept. 6, 2 – 3:30 p.m.

    Criteria for Defining Inadequate Response to Growth Hormone in Noonan Syndrome, Turner Syndrome, and SHOX Deficiency

    Poster #Sun-504

    Sunday, Sept. 7, 2 – 3:30 p.m.

    Fracture Incidence is Reduced and Bone Microarchitecure is Improved by CNP Analog Adjuvant Therapy in Young Mice with Moderate-to-Severe Osteogenesis Imperfecta

    Poster #Sun-542

    Sunday, Sept. 7, 2 – 3:30 p.m.

    Effect of Vosoritide on Spine Morphology in Young Children With Achondroplasia: 1-Year Results From a Double-Blind, Randomized Phase 2 Study

    Poster #Sun-555

    Sunday, Sept. 7, 2 – 3:30 p.m.

    Molecular Insights into C-Type Natriuretic Peptides Role in Enhancing Bone Growth and Mineralization

    Poster #Sun-133

    Sunday, Sept. 7, 2 – 3:30 p.m.

    ENPP1 Deficiency

    Accelerating Research and Development for Rare Bone Conditions in Europe: A Multistakeholder Call to Action

    Poster #Sat-583 (late-breaking)

    Saturday, Sept. 6, 2 – 3:30 p.m.

    Patient and Caregiver Insights on the Real-World Burden of the Rare Genetic Disorders, ENPP1 Deficiency and ABCC6 Deficiency

    Poster #Sat-352

    Saturday, Sept. 6, 2 – 3:30 p.m.

    Plasma Pyrophosphate (PPi) Levels Correlate with Severity of Clinical Manifestations in a Mouse Model of ENPP1 Deficiency

    Poster #Sun-298

    Sunday, Sept. 7, 2 – 3:30 p.m.

    Qualitative Evaluation of Hypophosphatemic Rickets Due to ENPP1 Deficiency

    Poster #Sun-352

    Sunday, Sept. 7, 2 – 3:30 p.m.

    About Achondroplasia

    Achondroplasia, the most common form of skeletal dysplasia, is characterized by impaired bone growth caused by a change in the FGFR3 gene. Bone growth is regulated by multiple biological processes including signaling pathways through fibroblast growth factor (FGF, which slows bone growth) and C-type natriuretic peptide (CNP, which increases bone growth). In achondroplasia, these signals are out of balance, resulting in a slowing of endochondral ossification, and causing disproportionate short stature and disordered architecture in the long bones, spine, face, and base of the skull.

    More than 80% of children with achondroplasia have parents of average stature and have the condition as a result of a spontaneous gene mutation. The worldwide incidence rate of achondroplasia is about one in 25,000 live births. VOXZOGO is being evaluated in children whose growth plates are still "open," typically those under 18 years of age. Approximately 25% of people with achondroplasia fall into this category.

    About ENPP1 Deficiency

    ENPP1 deficiency is a rare genetic condition caused by changes in the ENPP1 gene, leading to progressive damage to blood vessels, soft tissues and bones. Infants with this condition are often diagnosed with generalized arterial calcification of infancy (GACI) Type 1, and about 50% of them do not survive beyond six months. Children with ENPP1 deficiency typically develop a type of rickets called autosomal-recessive hypophosphatemic rickets type 2 (ARHR2), while adolescents and adults may develop osteomalacia (softened bones), both of which may cause pain and difficulty with movement. Individuals may also experience hearing loss, calcification in arteries and joints, and heart problems.

    BMN 401 (formerly INZ-701) is a potential first-in-disease treatment for ENPP1 deficiency, and initial pivotal data from the ENERGY 3 study in children ages 1-12 years is anticipated in the first half of 2026, with potential launch in 2027.

    About VOXZOGO

    In children with achondroplasia, endochondral bone growth, an essential process by which bone tissue is created, is negatively regulated due to a gain of function mutation in FGFR3. VOXZOGO, a C-type natriuretic peptide (CNP) analog, acts as a positive regulator of the signaling pathway downstream of FGFR3 to promote endochondral bone growth.

    VOXZOGO is approved in the U.S., Japan and Australia to increase linear growth in children of all ages with achondroplasia with open epiphyses, and VOXZOGO is indicated in the EU for the treatment of achondroplasia in children 4 months of age and older whose epiphyses are not closed, as confirmed by appropriate genetic testing. In the U.S., this indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trial(s). To fulfill this post-marketing requirement, BioMarin intends to use the ongoing open-label extension studies compared to available natural history.

    Patient Support Accessing VOXZOGO

    To reach a BioMarin RareConnections® Case Manager, please call, toll-free, 1-833-VOXZOGO (1-833-869-9646) or e-mail [email protected]. For more information about VOXZOGO, please visit www.voxzogo.com. For additional information regarding this product, please contact BioMarin Medical Information at [email protected].

    VOXZOGO U.S. Important Safety Information

    What is VOXZOGO used for?

    • VOXZOGO is a prescription medicine used to increase linear growth in children with achondroplasia and open growth plates (epiphyses).
    • VOXZOGO is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

    What is the most important safety information about VOXZOGO?

    • VOXZOGO may cause serious side effects including a temporary decrease in blood pressure in some patients. To reduce the risk of a decrease in blood pressure and associated symptoms (dizziness, feeling tired, or nausea), patients should eat a meal and drink 8 to 10 ounces of fluid within 1 hour before receiving VOXZOGO.

    What are the most common side effects of VOXZOGO?

    • The most common side effects of VOXZOGO include injection site reactions (including redness, itching, swelling, bruising, rash, hives, and injection site pain), high levels of blood alkaline phosphatase shown in blood tests, vomiting, joint pain, decreased blood pressure, and stomachache. These are not all the possible side effects of VOXZOGO. Ask your healthcare provider for medical advice about side effects, and about any side effects that bother the patient or that do not go away.

    How is VOXZOGO taken?

    • VOXZOGO is taken daily as an injection given under the skin, administered by a caregiver after a healthcare provider determines the caregiver is able to administer VOXZOGO. Do not try to inject VOXZOGO until you have been shown the right way by your healthcare provider. VOXZOGO is supplied with Instructions for Use that describe the steps for preparing, injecting, and disposing VOXZOGO. Caregivers should review the Instructions for Use for guidance and any time they receive a refill of VOXZOGO in case any changes have been made.
    • Inject VOXZOGO 1 time every day, at about the same time each day. If a dose of VOXZOGO is missed, it can be given within 12 hours from the missed dose. After 12 hours, skip the missed dose and administer the next daily dose as usual.
    • The dose of VOXZOGO is based on body weight. Your healthcare provider will adjust the dose based on changes in weight following regular check-ups.
    • Your healthcare provider will monitor the patient's growth and tell you when to stop taking VOXZOGO if they determine the patient is no longer able to grow. Stop administering VOXZOGO if instructed by your healthcare provider.

    What should you tell the doctor before or during taking VOXZOGO?

    • Tell your doctor about all of the patient's medical conditions including
      • If the patient has heart disease (cardiac or vascular disease), or if the patient is on blood pressure medicine (anti-hypertensive medicine).
      • If the patient has kidney problems or renal impairment.
      • If the patient is pregnant or plans to become pregnant. It is not known if VOXZOGO will harm the unborn baby.
      • If the patient is breastfeeding or plans to breastfeed. It is not known if VOXZOGO passes into breast milk.
    • Tell your doctor about all of the medicines the patient takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

    You may report side effects to BioMarin at 1-866-906-6100. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

    Please see additional safety information in the full Prescribing Information and Patient Information.

    About BioMarin

    BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that offer new possibilities for people living with genetically defined conditions around the world. To learn more, please visit www.biomarin.com.

    Forward-Looking Statements

    This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including without limitation, statements about: data presented at the American Society for Bone and Mineral Research (ASBMR) 2025 Annual Meeting, including the oral and poster presentations; VOXZOGO's efficacy, safety and impact on children with achondroplasia, including the potential positive impact on spinal morphology, ability to significantly improve growth in children who receive the medicine after puberty onset, and the potential to reduce the significant complications associated with achondroplasia in children; VOXZOGO's potential benefits, safety and impact on children with hypochondroplasia, Noonan syndrome, Turner syndrome and SHOX deficiency; and BioMarin's plans and expectations for the development of BMN 401, including the expected initial pivotal data readout for the ENERGY 3 study in children ages 1-12 years with ENPP1 deficiency in the first half of 2026, with potential launch in 2027. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: results and timing of current and planned pre-clinical studies and clinical trials of VOXZOGO and BMN 401; any potential adverse events observed in the continuing monitoring of the patients in the clinical trials; the content and timing of decisions by the U.S. Food and Drug Administration, the European Medicines Agency, the European Commission and other regulatory authorities; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, as such factors may be updated by any subsequent reports. Investors are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

    BioMarin®, BioMarin RareConnections® and VOXZOGO® are registered trademarks of BioMarin Pharmaceutical Inc.

    Contacts:



    Investors

    Media

    Traci McCarty

     Andrew Villani

    BioMarin Pharmaceutical Inc.

     BioMarin Pharmaceutical Inc.

    (415) 455-7558

     (628) 269-7393

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-shares-new-data-reinforcing-its-leadership-in-bone-health-at-the-american-society-for-bone-and-mineral-research-annual-meeting-302548021.html

    SOURCE BioMarin Pharmaceutical Inc.

    Get the next $BMRN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BMRN

    DatePrice TargetRatingAnalyst
    9/8/2025$60.00Neutral
    H.C. Wainwright
    9/3/2025$85.00Outperform
    Raymond James
    7/3/2025$97.00Overweight
    Morgan Stanley
    2/24/2025$98.00Perform → Outperform
    Oppenheimer
    11/15/2024$95.00Outperform
    Wolfe Research
    10/30/2024Outperform → Mkt Perform
    William Blair
    10/10/2024$79.00Outperform
    Raymond James
    8/20/2024$94.00 → $110.00Mkt Perform → Outperform
    Bernstein
    More analyst ratings

    $BMRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Clark Ian T was granted 7,000 shares (SEC Form 4)

    4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

    8/5/25 6:55:48 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Clark Ian T

    3 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

    8/5/25 6:51:51 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Commercial Officer Hubbard Cristin covered exercise/tax liability with 2,155 shares, decreasing direct ownership by 7% to 30,545 units (SEC Form 4)

    4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

    5/22/25 5:02:57 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on BioMarin Pharmaceutical with a new price target

    H.C. Wainwright initiated coverage of BioMarin Pharmaceutical with a rating of Neutral and set a new price target of $60.00

    9/8/25 8:48:48 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on BioMarin Pharmaceutical with a new price target

    Raymond James initiated coverage of BioMarin Pharmaceutical with a rating of Outperform and set a new price target of $85.00

    9/3/25 8:29:10 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley resumed coverage on BioMarin Pharmaceutical with a new price target

    Morgan Stanley resumed coverage of BioMarin Pharmaceutical with a rating of Overweight and set a new price target of $97.00

    7/3/25 7:59:58 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting

    Children who received VOXZOGO showed anatomical improvements in spinal morphology VOXZOGO continued to significantly improve growth in children who received the medicine after puberty onset SAN RAFAEL, Calif., Sept. 8, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced new data from 14 studies were presented at the American Society for Bone and Mineral Research 2025 (ASBMR) Annual Meeting in Seattle, including results demonstrating treatment with VOXZOGO® (vosoritide) led to anatomical improvements in spinal morphology in young children, and continued efficacy in children who received the medicine after the onset of puberty.

    9/8/25 9:00:00 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism

    New data from Phase 3 PEGASUS study demonstrates a 49.7% decrease in mean blood Phe levels in adolescents aged 12-17 treated with PALYNZIQ BioMarin's planned submission to global health authorities on track for second half of 2025 SAN RAFAEL, Calif., Sept. 6, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced new data characterizing the efficacy and safety of PALYNZIQ® (pegvaliase-pqpz) for the treatment of adolescents with phenylketonuria (PKU), which were presented at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan, Sept. 2-6, 2025.

    9/6/25 11:05:00 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioMarin to Participate in Upcoming Investor Conferences

    Cantor Global Healthcare Conference, September 3 at 8:00 am ESTWells Fargo Healthcare Conference, September 4 at 8:45 am ESTMorgan Stanley Global Healthcare Conference, September 9 at 11:30 am ESTSAN RAFAEL, Calif., Aug. 27, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that management will present at upcoming investor conferences in September. An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company

    8/27/25 9:00:00 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by BioMarin Pharmaceutical Inc.

    SCHEDULE 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)

    8/14/25 12:43:58 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioMarin Pharmaceutical Inc. filed SEC Form 8-K: Leadership Update

    8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)

    8/11/25 4:02:59 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by BioMarin Pharmaceutical Inc.

    S-8 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)

    8/5/25 4:13:30 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 29, 2023 - FDA Approves First Gene Therapy for Adults with Severe Hemophilia A

    For Immediate Release: June 29, 2023 Today, the U.S. Food and Drug Administration approved Roctavian, an adeno-associated virus vector-based gene therapy for the treatment of adults with severe hemophilia A without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test. “Hereditary hemophilia A is a potentially serious bleeding disorder. Severe cases of hemophilia A can ca

    6/29/23 6:02:12 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRN
    Leadership Updates

    Live Leadership Updates

    View All

    BioMarin Announces Appointment of Ian T. Clark to Board of Directors

    SAN RAFAEL, Calif., Aug. 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that the company has appointed Ian T. Clark to the company's Board of Directors, effective today, August 1, 2025. Mr. Clark served as Chief Executive Officer of Genentech and a member of the company's Board of Directors from 2010 until his retirement in 2016. Under his leadership, Genentech launched 15 new drugs. Prior to serving as CEO, Mr. Clark held a number of senior management positions at Genentech. Before joining Genentech, Mr. Clark spent 23 years in the biopharmaceuti

    8/1/25 9:00:00 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

    3/11/25 7:00:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    $BMRN
    Financials

    Live finance-specific insights

    View All

    BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS

    Second Quarter 2025 Total Revenues of $825 million (+16% Y/Y and +17% at Constant Currency Y/Y) Second Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $1.23 (+124% Y/Y) Second Quarter 2025 Non-GAAP Diluted EPS of $1.44 (+50% Y/Y) BioMarin Completes Acquisition of Inozyme in July 2025; Pivotal Data from Lead Indication Expected 1H'26 BMN 333 Exceeds Targeted Exposures of Free C-type Natriuretic Peptide (CNP) in Healthy Volunteer Study; Pivotal Phase 2/3 Study with BMN 333 in Pediatric Achondroplasia Planned to Begin 1H'26 Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif., Aug. 4, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced

    8/4/25 4:02:00 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET

    SAN RAFAEL, Calif., July 22, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, August 4, 2025, at 4:30 p.m. ET to discuss second quarter 2025 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 800-715-9871International Dial-in Number: 646-307-1963Conference Call ID: 6336054  U.S. / Canada Replay Dial-in Number: 800-770-2030International Replay Dial-in Number: 609-800-9909Play

    7/22/25 9:00:00 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioMarin Announces Completion of Acquisition of Inozyme

    SAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (NASDAQ:INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones. On May 16, 2025, BioMarin and Inozyme announced tha

    7/1/25 8:45:00 AM ET
    $BMRN
    $INZY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by BioMarin Pharmaceutical Inc.

    SC 13G - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)

    9/30/24 4:29:01 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by BioMarin Pharmaceutical Inc.

    SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)

    7/10/24 1:14:41 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by BioMarin Pharmaceutical Inc.

    SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)

    7/8/24 4:32:41 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care